GLP-1 Dose Response: Titration, Plateaus, Missed Doses, and Microdosing Explained

What "Dose Response" Means for GLP-1 Drugs

The dose-response relationship for GLP-1 receptor agonists is one of the most consistent findings in recent obesity pharmacology. Higher doses suppress appetite more, slow gastric emptying more, and produce proportionally greater weight loss, up to a ceiling set by each drug's maximum approved dose. The relationship is not strictly linear; each dose increment produces smaller marginal gains than the one before, which is why the titration schedule matters as much as the target dose itself.

In STEP-1 (N=1,961), participants randomized to semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% on placebo [1]. The dose-response gradient within the STEP program is visible across trials: STEP-2 (N=1,210, patients with type 2 diabetes) showed 9.6% weight loss at the same 2.4 mg dose versus 3.4% on placebo, with the attenuated effect reflecting insulin-resistance-related differences in drug sensitivity [2]. The Lancet authors noted that even the 1.0 mg dose used for glycemic control in Ozempic produced meaningful but smaller reductions than the 2.4 mg obesity dose.

Tirzepatide adds a GIP receptor agonist component to GLP-1 activity, and that dual mechanism shifts the entire dose-response curve upward. In SURMOUNT-1 (N=2,539), tirzepatide 5 mg produced 15.0% weight loss, 10 mg produced 19.5%, and 15 mg produced 20.9% at 72 weeks, all versus 3.1% on placebo [3]. Each 5 mg step added approximately 4 to 5 percentage points of additional weight loss, a steeper incremental gain than seen with semaglutide's titration steps.

The clinical takeaway: both drugs justify titrating to the highest tolerated dose, because leaving efficacy on the table by staying at a sub-maintenance dose is a documented source of treatment failure.

The Standard Titration Schedule for Semaglutide and Tirzepatide

Titration is a safety mechanism. The slow dose escalation trains gastrointestinal receptors to tolerate increasing GLP-1 activity, reducing nausea, vomiting, and the dropout that comes with them. The Wegovy FDA label specifies a five-step schedule across 16 weeks [4].

Wegovy (semaglutide 2.4 mg) titration:

| Weeks | Dose | |-------|------| | 1-4 | 0.25 mg once weekly | | 5-8 | 0.5 mg once weekly | | 9-12 | 1.0 mg once weekly | | 13-16 | 1.7 mg once weekly | | 17+ | 2.4 mg once weekly (maintenance) |

Zepbound (tirzepatide) titration:

The Zepbound FDA label specifies a minimum 4-week interval at each dose step [5]. The standard path to the 15 mg ceiling takes 20 weeks: 2.5 mg (weeks 1-4), 5 mg (weeks 5-8), 10 mg (weeks 9-12 or longer), then 15 mg. Prescribers may extend any step if tolerability is poor.

Ozempic (semaglutide for type 2 diabetes) uses a compressed three-step schedule: 0.25 mg for 4 weeks, then 0.5 mg, with optional increases to 1.0 mg or 2.0 mg if glycemic targets are not met after at least 4 weeks at each dose [4].

Dose injections go subcutaneously into the abdomen, upper thigh, or upper arm. Rotating sites within each region reduces injection-site reactions. Day of week should stay fixed; the consistency maintains steady-state plasma concentrations, since semaglutide's half-life is approximately 1 week [4].

One practical complication: the 0.25 mg starting pen and the 2.4 mg maintenance pen are different devices. Patients switching pens mid-titration should confirm device type with their pharmacy.

When to Increase the Dose and How to Know It Is Working

Dose increases follow time, not the scale. The minimum interval at each semaglutide dose step is 4 weeks. Increasing faster than that does not improve weight outcomes and raises nausea rates substantially. STEP-1 participants who completed full titration had a dropout rate of 7.3% versus rates above 20% reported in real-world cohorts where titration was compressed [1].

Clinically meaningful response at any given dose step is roughly 2 to 4 weeks of consistent appetite suppression and early weight movement. The American Association of Clinical Endocrinology (AACE) obesity guidelines state that a 5% weight reduction from baseline at 12 to 16 weeks is the minimum response threshold warranting continued treatment [6]. Patients who do not reach that threshold may need dose escalation, adjunct behavioral intervention, or reassessment of secondary causes of weight resistance.

Signs that a patient is ready to escalate:

• GI side effects have resolved or become mild at the current dose
• Weight loss has slowed but has not plateaued for 12 consecutive weeks
• At least 4 weeks have elapsed at the current step

Signs to hold the current dose rather than escalate:

• Active nausea or vomiting more than twice per week
• Less than 4 weeks at the current step
• Recent travel, illness, or significant dietary change confounding the response

Missed Doses: What the Label Says and What the Data Show

Missing a dose of semaglutide is common. The FDA-approved Wegovy labeling provides a specific rule: if a dose is missed, inject it as soon as possible within 5 days of the scheduled day. If more than 5 days have passed, skip that dose and resume on the next scheduled injection day. Do not double-dose [4].

This rule follows from semaglutide's pharmacokinetics. The drug reaches steady-state concentration after approximately 4 to 5 weeks of weekly dosing and has a terminal half-life of about 7 days. Missing one injection drops plasma levels but not to zero; a single missed week does not fully reverse appetite suppression or glycemic control. Animal pharmacokinetic modeling and the package insert rationale both support the 5-day window as the point at which plasma concentrations have fallen enough that re-dosing on the original schedule is the safer option.

Tirzepatide's labeling applies the same logic: inject the missed dose within 4 days of the scheduled date. If more than 4 days have elapsed, skip and continue on the regular schedule [5].

What patients typically notice after a missed dose is a return of appetite in days 5 to 7, sometimes called the "week-7 hunger window" in clinical practice. This rebound is transient. Resuming the next scheduled dose restores appetite suppression within 48 to 72 hours in most patients.

A missed dose does not require restarting titration. The exception is a gap of 2 or more consecutive weeks, particularly during early titration. If a patient misses 2 or more weeks at the 0.25 mg or 0.5 mg stage, the prescribing clinician should decide whether to restart from 0.25 mg to avoid compounding GI intolerance on re-exposure.

GLP-1 Weight-Loss Plateaus: Mechanism and Management

Weight loss on GLP-1 drugs does not continue indefinitely. Plateaus are expected. They are a physiological feature, not a failure of the drug.

STEP-5 (N=304 to 104 weeks of semaglutide 2.4 mg) tracked the long-term weight trajectory and found that the majority of weight loss occurred in the first 60 weeks, with a plateau emerging between weeks 60 and 104 [7]. Mean body weight at week 104 was 15.2% below baseline, virtually identical to the week-68 result in STEP-1. The plateau reflects a new energy-balance set point, not drug tolerance in the pharmacological sense.

Several mechanisms drive the plateau:

1. Reduced resting metabolic rate as body mass falls. A 15% weight reduction lowers total daily energy expenditure by roughly 150 to 300 kcal/day in a 100 kg person, narrowing the caloric deficit.
2. Compensatory increases in hunger signaling from ghrelin and peptide YY rebound, partially offsetting GLP-1-mediated suppression.
3. Behavioral adaptation. Patients often reintroduce caloric foods as nausea resolves and appetite partially returns.

Strategies with evidence:

• Dose escalation if not at maximum. SURMOUNT-1 showed each tirzepatide dose step added an additional 4 to 5% weight loss [3]. If a patient is at 10 mg tirzepatide and tolerating it, escalating to 15 mg is the most evidence-backed move.
• Structured dietary recalibration. STEP-3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy and produced 16.0% weight loss versus 5.7% with behavioral therapy alone, confirming that behavioral components add incremental benefit [8].
• Combination assessment. SURMOUNT-3 (N=806) pre-treated participants with intensive lifestyle intervention before initiating tirzepatide, achieving 24.5% mean weight loss at 72 weeks, the highest reported in any major GLP-1 RCT [9]. This suggests the metabolic state at drug initiation influences the ceiling achievable.
• Drug switch. STEP-8 (N=338) showed semaglutide 2.4 mg outperformed liraglutide 3.0 mg: 15.8% vs. 6.4% weight loss at 68 weeks [10]. A patient plateauing on liraglutide may benefit from switching to semaglutide or tirzepatide.

What does not address a true pharmacological plateau: adjusting injection timing within the week, changing injection site, or taking the drug with or without food. These variables do not materially alter systemic bioavailability.

Microdosing GLP-1 Drugs: Off-Label Practice and What the Evidence Actually Shows

Microdosing refers to using doses below the approved starting dose, typically 0.1 mg to 0.15 mg of semaglutide weekly, in an attempt to gain partial appetite suppression with fewer GI side effects. This practice has grown among compounding pharmacy users and patients who are GI-sensitive.

No randomized controlled trial has evaluated microdosing for weight loss. The practice is entirely off-label, and no microdosing schedule appears in any FDA-approved labeling [4]. What the available pharmacology does support is that GLP-1 receptor agonism is dose-dependent, meaning sub-therapeutic doses produce sub-therapeutic effects. The 0.25 mg starting dose in the Wegovy schedule was itself chosen as the minimum dose expected to produce detectable receptor occupancy while tolerability is established.

The theoretical rationale for extended microdosing is incremental receptor desensitization below the nausea threshold. In practice, some clinicians use a modified protocol starting at 0.1 mg or 0.15 mg weekly for 4 to 8 weeks before advancing to 0.25 mg, particularly in patients who discontinued a prior GLP-1 due to severe nausea. This is a tolerance-building maneuver, not a long-term dosing strategy.

The HealthRX clinical team uses the following framework for patients requesting microdose starts:

HealthRX Microdose Decision Framework (for patients with prior GLP-1 intolerance):

1. Confirm prior intolerance was GI-related, not allergic or cardiac.
2. Start at 0.1 mg weekly for 4 weeks if compounded semaglutide is prescribed, or use the lowest available pen dose for brand-name products.
3. Advance to 0.25 mg weekly only after 4 weeks without grade 2 or higher nausea (NCI CTCAE scale).
4. Resume standard Wegovy or Zepbound titration schedule once 0.25 mg is tolerated.
5. Document rationale and informed consent for off-label dosing in the chart.

Patients should understand that microdosing extends the pre-therapeutic phase. Weight loss is unlikely to be clinically meaningful below 0.5 mg weekly in most individuals.

Cardiovascular Dose-Response: What SELECT Adds

The dose-response story extends beyond weight. SELECT (N=17,604) randomized patients with overweight or obesity and established cardiovascular disease to semaglutide 2.4 mg versus placebo. At a mean follow-up of 39.8 months, semaglutide reduced major adverse cardiovascular events (MACE) by 20% (HR 0.80 to 95% CI 0.72-0.90, P<0.001) [11]. The cardiovascular benefit appeared independent of the degree of weight loss, suggesting direct vascular effects of GLP-1 receptor agonism separate from adiposity reduction.

The FDA-approved Wegovy label was updated in 2024 to include a cardiovascular risk reduction indication specifically for patients with BMI ≥27 and established cardiovascular disease, the first time an anti-obesity drug has received this indication [4]. This changes the dose-response calculus: for high-risk cardiovascular patients, the full 2.4 mg maintenance dose carries both metabolic and cardiovascular justification, and undertreatment at a sub-maintenance dose may carry meaningful cardiovascular opportunity cost.

SURMOUNT-4 (N=670) addressed what happens when tirzepatide is withdrawn after a maintenance period. Patients who continued tirzepatide maintained 5.5% additional weight loss at 88 weeks, while those switched to placebo regained 14.8% of body weight [12]. The trial confirms that the dose-response benefit of GLP-1 and dual GIP/GLP-1 agonism requires continuous dosing to sustain; there is no durable weight-reset after discontinuation.

Injection Technique and Its Effect on Drug Absorption

Dose-response is partly a function of consistent absorption, and absorption varies with injection technique. Subcutaneous injection into the correct tissue plane, 4 to 6 mm below the skin surface for most adults, delivers drug into the subcutaneous fat where it is absorbed slowly and predictably. Injecting too shallowly (intradermal) or too deeply (intramuscular) alters the absorption rate and may increase local reactions or cause erratic plasma levels.

Practical technique points that affect the dose-response curve in practice:

• Inject at room temperature. Cold drug from the refrigerator increases injection-site pain and may slow absorption marginally.
• Do not inject into lipohypertrophic tissue. Fibrous subcutaneous tissue from repeated injections at the same site reduces vascular supply and slows absorption.
• The abdomen provides the most consistent absorption. Thigh and upper arm are acceptable alternatives. The FDA label does not rank sites by absorption speed, but subcutaneous abdominal pharmacokinetics are the most studied [4].
• Pen device priming: one flow-check before the first use of a new pen ensures the needle is patent.

In a patient reporting poor response at a dose they have tolerated for 8 or more weeks, injection technique review is a reasonable first step before escalating dose.

Interpreting Non-Response: When the Dose Is Not the Problem

A subset of patients on maximally titrated GLP-1 therapy do not reach the AACE 5% weight-loss threshold at 12 to 16 weeks [6]. Before attributing this to pharmacological resistance, the differential includes:

• Caloric compensation. Appetite suppression reduces spontaneous eating, but some patients consciously or unconsciously increase caloric density of remaining meals.
• Secondary hypothyroidism or Cushing syndrome. Undiagnosed endocrine causes of weight resistance may blunt response. TSH and morning cortisol are reasonable screens in true non-responders.
• Drug-drug interactions. GLP-1-mediated gastric emptying delay can reduce oral medication absorption, including oral contraceptives and levothyroxine. This rarely affects weight outcomes but affects co-medication efficacy.
• Antibody formation. Neutralizing antibodies to semaglutide were detected in 0.5% of STEP-1 participants; none were confirmed to cross-react with endogenous GLP-1 and none were associated with reduced efficacy in those participants [1]. This is a rare and unlikely cause of non-response.
• Adherence gaps. Real-world data consistently show adherence rates 20 to 30% lower than clinical trial rates. A frank conversation about missed doses and injection technique precedes any dose escalation decision.

The AACE guidelines recommend reassessing treatment strategy if a patient has not achieved 5% weight loss at 16 weeks on the target dose [6]. That reassessment should consider switching agents, adding adjunct pharmacotherapy, or bariatric surgical consultation rather than simply repeating the same prescription.